STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES

ERGOTAMINE-CAFFEINE

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
ERGOTAMINE TARTRATE/CAFFEINE	MIGERGOT	01868		GPI-10 (6799100210)	ROUTE ≠ ORAL

GUIDELINES FOR USE

1. Is Migergot being used to abort or prevent vascular headaches (e.g., migraine, migraine variants, so-called 'histaminic cephalalgia') and the patient meets **ALL** of the following criteria?
   - The patient cannot swallow ergotamine/caffeine tablets
   - The patient had a trial of or contraindication to generic ergotamine/caffeine tablets AND two triptans (e.g., sumatriptan, rizatriptan)

   If yes, **approve for 12 months by GPID or GPI-14 with a quantity limit of #24 per 30 days.** If no, do not approve.
   DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

   Our guideline named **ERGOTAMINE-CAFFEINE (Migergot)** requires the following rule(s) be met for approval:
   A. Migergot is being used to abort (stop) or prevent vascular headaches (such as migraines, migraine variants, so-called 'histaminic cephalalgia' [types of headaches])
   B. You cannot swallow ergotamine/caffeine tablets
   C. You had a trial of or contraindication (harmful for) to generic ergotamine/caffeine tablets AND two triptans (such as sumatriptan, rizatriptan)

   Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RATIONALE

For further information, please refer to the Prescribing Information and/or Drug Monograph for Migergot.

REFERENCES

- Migergot [Prescribing Information]. South Plainfield, NJ: Cosette Pharmaceuticals, Inc., August 2019.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A
Commercial Effective:04/01/23
Created: 11/22
Client Approval: 02/23
P&T Approval: 10/22